Home › Triple-Negative Breast Cancer › Pennsylvania › Pittsburgh
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Pittsburgh, PA
Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Pittsburgh. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Nagre-recruit
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Nagre-recruitPhase 1
- UPMC, Pittsburgh
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Nagre-recruitPhase 3
- UPMC Magee-Womens Hospital, Pittsburgh
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Nagre-recruitPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site, Pittsburgh
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Local Institution - 0360, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- Allegheny Health Network, Pittsburgh
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
Nagre-recruitObservasyonal na pag-aaral
- UPMC Hillman Cancer, Pittsburgh
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Nagre-recruitPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod
- Houston, TX42 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN27 pag-aaral
- Los Angeles, CA26 pag-aaral
- Boston, MA26 pag-aaral
- San Antonio, TX22 pag-aaral
- St. Louis, MO21 pag-aaral
- Arlington, VA20 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX18 pag-aaral
- Columbus, OH16 pag-aaral
- Chicago, IL16 pag-aaral
Iba pang pag-aaral sa Pittsburgh
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Kanser sa Suso40 pag-aaral
- Colorectal Cancer32 pag-aaral
- Kanser sa Ovary31 pag-aaral
- Metastatic Cancer31 pag-aaral
- Melanoma31 pag-aaral
- Kanser ng Endometrium23 pag-aaral
- Kanser sa Prostate23 pag-aaral
- Kanser sa Baga23 pag-aaral
- Stroke22 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg22 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 7, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.